Open Medicine · Published 2026-01-01 · DOI 10.1515/med-2026-1406
To investigate the neuroprotective effects of adalimumab against cisplatin-induced cognitive impairment (CICI) and to evaluate its potential to ameliorate anxiety- and depression-like behaviors as well as learning and memory deficits through modulation of Tumor necrosis factor-α (TNF-α)–mediated neuroinflammation, cholinergic homeostasis, and apoptosis.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →